Please use this identifier to cite or link to this item: http://ir.library.ui.edu.ng/handle/123456789/2268
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFasola, F. A.-
dc.contributor.authorOdaibo, G. N.-
dc.contributor.authorAken'ova, Y. A.-
dc.contributor.authorOlaleye, O. D.-
dc.date.accessioned2018-10-12T11:36:30Z-
dc.date.available2018-10-12T11:36:30Z-
dc.date.issued2003-
dc.identifier.otherAfrican Journal of Medical Science 32,pp. 293-295-
dc.identifier.urihttp://ir.library.ui.edu.ng/handle/123456789/2268-
dc.description.abstractSerum samples from 180 Sickle Cell Disease (SCD) patients attending Medical Out patients (MOP) clinic of the Department of Haematology, UCH, Ibadan, Nigeria were tested for the presence of HbsAg and anti-HCV in their blood samples. The result showed that HBV infection was slightly higher (not significant) than HCV infection among SCD patients (P>0.05). In addition, the result showed that the mean number of transfusion was higher among patients who were sero-positive for both HbsAg (5.0 +/- 6.6) and anti-HCV (4.6 +/- 6.7) when compared to patients who were negative for both viruses (2.7 +/- 3.0 and 2.9 +/- 3.2) for HBsAg and anti-HCV respectively. These observations is an indication that there is an urgent need to screen blood units for hepatitis B and C virus infections prior to transfusion in order to reduce HCV infection among SCD patients in Nigeria. Furthermore, it suggests the need to vaccinate SCD patients against HBV in this environment.en_US
dc.language.isoenen_US
dc.titleHepatitis B and C viral markers in patients with sickle cell disease in Ibadan, Nigeriaen_US
dc.typeArticleen_US
Appears in Collections:scholarly works

Files in This Item:
File Description SizeFormat 
(14)ui_art_fasola_hepatitis_2003.pdf1.18 MBAdobe PDFThumbnail
View/Open


Items in UISpace are protected by copyright, with all rights reserved, unless otherwise indicated.